PTC Therapeutics Inc (NASDAQ: PTCT) is a biopharmaceutical company that develops and commercializes medicines for rare disorders. The company generates revenue through product sales of its approved therapeutics and pursues additional income through named patient and cohort early access programs in markets where formal regulatory approval is pending. The filing excerpts identify an eligible patient base and commercial potential across its products and product candidates as central to its revenue outlook, along with reimbursement arrangements with payers. PTC Therapeutics also pursues acquisitions and strategic transactions as a path to expanding its pipeline. The company acknowledges reliance on third-party discounts and rebates as a factor shaping net revenue realization. The excerpts do not provide specific revenue figures, segment breakdowns, founding year, headquarters, CEO name, or named competitors from this filing.

Revenue model

Product sales of approved rare disease therapeutics, supplemented by named patient and cohort early access programs in markets without full marketing approval. Revenue is subject to third-party discounts and rebates.

Products and services

Approved therapeutic products and clinical-stage product candidates targeting rare disorders. Specific product names are not supported by the provided filing excerpts.

Customers and end markets

Patients with rare diseases, accessed through reimbursed named patient programs, cohort early access programs, and standard commercial channels. Payers and reimbursement bodies are material counterparties.

Value-chain role

Drug developer and commercial-stage biopharmaceutical company. Acquires pipeline assets through strategic transactions in addition to internal development.

Geographic exposure

The filing references named patient and cohort early access programs, suggesting multi-market international commercial activity, but specific geographies and revenue splits are not supported by the provided excerpts.

Source: SEC 10-K, filed 2026-02-19

Industry: Pharmaceutical Preparations Peers: AMICUS THERAPEUTICS, INC. Arrowhead Pharmaceuticals Inc Beam Therapeutics Inc Blueprint Medicines Corp ChemoCentryx, Inc. Denali Therapeutics Inc Intellia Therapeutics Inc Mirati Therapeutics, Inc.